Logo

Call Harley Cosmetic Group on : 08454961497

International : +44 2032900275

Preventive breast cancer surgery and breast augmentation

This was obvious even a decade ago when a breast augmentation surgery was considered by majority of fashion hyped persons, women body builders and the trendy and rich community. Terms like micromastia and asymmetric breasts didn’t compel commoner women to go for breast implants until perhaps the word mastectomy came into the scene. Breast Augmentation surgeries are nonetheless widening nowadays being the most commonly sought surgery in the UK.

Hereditary breast/ovarian cancer syndrome (HBOC) is an alarming syndrome which means to genetically inherit breast or ovarian cancer and increasing risks associated with it. Women who are diagnosed with BRCA 1 or 2 mutation following pain, discomfort or ptosis in the breast often choose preventive breast cancer surgery that is to surgically remove one’s infected breasts including breasts glands and breast tissue from its roots or the core areas before it starts to spread to cause more harm. Following mastectomy (medical term for surgical removal of breasts) a breast augmentation surgery is conducted to reconstruct the loss of the natural breasts with artificial breast implants.

Preventive breast cancer surgery and breast augmentation

Mastectomy doesn’t only apply for patients with breast cancer. Patients can be detected with lumps that are not cancerous tumors and lumpectomy is performed with open excision or medication of the breasts and removing the lumps. Sometimes this happens over again, and after about 2 or 3 times bearing the surgery, surgical trauma and of course surgical costs patients often opt for permanent mastectomy—this is one case of preventive breast cancer surgery. And also to keep chemotherapy at bay.

Radiotherapy for breast cancer- Lumpectomy and XRT is a good method for breast conservation in select types of breast cancer, however once the disease is controlled, the challenges begin. Radiation affects all components of the breast, starting with the skin, the tumor bed and surrounding breast tissue. Radiation is intended to kill microscopic foci of breast cancer; however it can also cause shrinkage of the remaining breast tissue, so that the affected breast becomes \”static\”, while the opposite side continues to age, droop, and enlarge. So the problem is asymmetry, which can be corrected by reshaping the cancer side or both breasts by augmentation, lift, reduction, etc.

The big \”caveat\” or warning is that the affected breast will usually experience delays in wound healing, be more prone to infection and have the asymmetry recur. Not to discourage you, but external beam radiation therapy can make any reconstructive surgeon humble. Stay tuned, for the development of IORT (intra-operative radiation therapy) for tumors which conform to a specific size and single focus. Things are changing, hopefully for the better.

Breast enlargement consists of creating a pocket, big enough to accept the selected implant, which is often placed between the breast tissue and the pectoral muscle, although in some cases is placed behind the pectoral muscle (very thin skin, lack of breast tissue). The result is very individual and will depend a lot on the shape of the breasts beforehand, the quality of skin etc. Breast enlargement is a very safe, quick and common procedure these days, which produces amazingly natural results.

Absolutely, there is no reason what so ever why you cannot breast feed. The lactic ducts are not interfered with during the surgical procedure.

Breast Implants and risks of cancer

There is no evidence to provide this suspicion. Breast Implants DO NOT cause cancer it does not elevate it. However, there have been evident studies that breast cancer on implanted breast might elevate more than in natural breasts. The first thing to do is to get rid of the implants. But if you are not into a higher risk of cancer, having breast implants won’t cause you into it.

Life-saving, risk-reducing medical interventions are required for women with aBRCA1/2 mutation. Interventions comprise a four-stage approach that involves risk assessment, genetic counseling, gene-mutation analysis and medical intervention strategies. Genetic counseling should be offered at specialized familial breast-cancer clinics and gene-mutation analysis should be recommended on the basis of personal and family-history-based risk criteria. Prophylactic bilateral salpingo-oophorectomy appears to offer the optimal benefit–risk ratio compared with prophylactic bilateral mastectomy, chemoprevention, or intensified surveillance.

Tamoxifen is an alternative approach only for BRCA2 mutation carriers. The comprehensive, clinical decision-making Ioannina algorithm provided here can facilitate the complex preventive strategic approach. Newly diagnosed BRCA1/2 carriers might benefit from extensive surgery and a specific pharmacological treatment, but data to support this strategy are limited. Microarray gene-expression studies show that breast tumors from BRCA1 carriers are predominantly of basal subtype (i.e. triple negative) and BRCA2 carriers are of luminal subtype (i.e. estrogen-receptor-positive). Although optimum management of women with familial susceptibility to breast and ovarian cancer has not yet been prospectively validated, data indicate substantial benefits when an individualized evidence-based prevention strategy is provided by an experienced team.

Revision surgery following primary augmentation mammoplasty is commonly performed. There are several long-term and short-term published studies on the incidence of revisionary surgery in primary mammoplasties. The current study is a single surgeon\’s experience with reoperations following consecutively performed primary augmentation mammoplasties and an assessment of the role of the process of breast augmentation. A retrospective data analysis was performed to evaluate a single surgeon\’s 3-year reoperation rate in primary augmentation mammoplasties.

Methods

A retrospective analysis of data using the Excel Spread was performed. Data of patients having had consecutive primary augmentation mammoplasties, performed between January 2008 and December 2010, were collected to evaluate the efficacy of a structured process of primary augmentation mammoplasties and its impact on a 3-year reoperation rate. Patients with asymmetrical breast or chest requiring different size implants were excluded. Patients presenting with ptosis requiring mastopexy in primary breast augmentation were also excluded from the study.

Results A total of 507 primary bilateral augmentation mammoplasties were performed by the author between January 2008 and December 2010. All patients had muscle splitting biplane technique and all had round silicone cohesive gel silicone implants during the study period. All implants were inserted using inframammary crease incision. Mean size of implant in primary augmentation mammoplasty was 346.9 cc (range 200–700). Data showed 10 (1.97 %) patients had a reoperation following primary augmentation mammoplasty.

Conclusions This retrospective study showed a low 3-year reoperation rate. A clear understanding of the process of breast augmentation, good informed consent and careful selection of implant size in primary and revision augmentation mammoplasty can potentially reduce reoperations.

Information provided here is gathered from genuine research materials provided by first hand genuine studies conducted by highly qualified researchers. This is the latest assessment of the subject and keyword: Breast Implants, breast cancer, breast augmentation UK. The author is based in London. But reference is taken from studies conducted worldwide.